Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 1 |
2020 | 3 |
2022 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
brain gittleman
(51 results)?
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
Mol Cancer Ther. 2022 Mar 1;21(3):397-406. doi: 10.1158/1535-7163.MCT-21-0455.
Mol Cancer Ther. 2022.
PMID: 34965958
Free PMC article.
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.
Capasso A, Bagby SM, Dailey KL, Currimjee N, Yacob BW, Ionkina A, Frank JG, Kim DJ, George C, Lee YB, Benaim E, Gittleman B, Hartman SJ, Tan AC, Kim J, Pitts TM, Eckhardt SG, Tentler JJ, Diamond JR.
Capasso A, et al. Among authors: gittleman b.
Mol Cancer Ther. 2019 Nov;18(11):1916-1925. doi: 10.1158/1535-7163.MCT-18-1334. Epub 2019 Sep 5.
Mol Cancer Ther. 2019.
PMID: 31488700
Free PMC article.
Item in Clipboard
Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer.
Pitts TM, Simmons DM, Bagby SM, Hartman SJ, Yacob BW, Gittleman B, Tentler JJ, Cittelly D, Ormond DR, Messersmith WA, Eckhardt SG, Diamond JR.
Pitts TM, et al. Among authors: gittleman b.
Cancers (Basel). 2020 Mar 19;12(3):719. doi: 10.3390/cancers12030719.
Cancers (Basel). 2020.
PMID: 32204315
Free PMC article.
Item in Clipboard
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
Davis SL, Ionkina AA, Bagby SM, Orth JD, Gittleman B, Marcus JM, Lam ET, Corr BR, O'Bryant CL, Glode AE, Tan AC, Kim J, Tentler JJ, Capasso A, Lopez KL, Gustafson DL, Messersmith WA, Leong S, Eckhardt SG, Pitts TM, Diamond JR.
Davis SL, et al. Among authors: gittleman b.
Clin Cancer Res. 2020 Sep 1;26(17):4633-4642. doi: 10.1158/1078-0432.CCR-19-3498. Epub 2020 May 15.
Clin Cancer Res. 2020.
PMID: 32414750
Free PMC article.
Clinical Trial.
Item in Clipboard
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
Tentler JJ, Lang J, Capasso A, Kim DJ, Benaim E, Lee YB, Eisen A, Bagby SM, Hartman SJ, Yacob BW, Gittleman B, Pitts TM, Pelanda R, Eckhardt SG, Diamond JR.
Tentler JJ, et al. Among authors: gittleman b.
BMC Cancer. 2020 Nov 4;20(1):1063. doi: 10.1186/s12885-020-07500-1.
BMC Cancer. 2020.
PMID: 33148223
Free PMC article.
Item in Clipboard
Cite
Cite